Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Everolimus. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A known ✓ | P62942 | 9/20 | 0.87 |
| ▸ | MTOR | P42345 | 7/20 | 1.00 |
| ▸ | ABCC3 | O15438 | 2/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 2/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 2/20 | 1.00 |
| ▸ | ABCC2 | Q92887 | 2/20 | 1.00 |
| ▸ | RPTOR | Q8N122 | 2/20 | 1.00 |
| ▸ | MLST8 | Q9BVC4 | 2/20 | 1.00 |
| ▸ | KCNE1 | P15382 | 1/20 | 1.00 |
| ▸ | KCNQ1 | P51787 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 0.87 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.87 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Everolimus SCHEMBL22813561 | 1.00 | MTOR (1.00) | MTORABCC3ABCC4ABCB11ABCC2 | |
| Everolimus SCHEMBL23251030 | 1.00 | MTOR (1.00) | MTORABCC3ABCC4ABCB11ABCC2 | |
| Everolimus SCHEMBL23063577 | 1.00 | MTOR (1.00) | MTORABCC3ABCC4ABCB11ABCC2 | |
| Everolimus SCHEMBL20759396 | 1.00 | MTOR (1.00) | MTORABCC3ABCC4ABCB11ABCC2 | |
| Everolimus SCHEMBL25481687 | 1.00 | MTOR (1.00) | MTORABCC3ABCC4ABCB11ABCC2 | |
| Everolimus SCHEMBL23552755 | 1.00 | MTOR (1.00) | MTORABCC3ABCC4ABCB11ABCC2 | |
| Everolimus SCHEMBL23251039 | 1.00 | MTOR (1.00) | MTORABCC3ABCC4ABCB11ABCC2 | |
| Everolimus SCHEMBL24472605 | 1.00 | MTOR (1.00) | MTORABCC3ABCC4ABCB11ABCC2 | |
| Everolimus SCHEMBL23747774 | 1.00 | MTOR (1.00) | MTORABCC3ABCC4ABCB11ABCC2 | |
| Everolimus SCHEMBL22882345 | 1.00 | MTOR (1.00) | MTORABCC3ABCC4ABCB11ABCC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 84705 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144866-A1 | METHODS, DEVICES, AND SYSTEMS FOR PREDICTING TREATMENT RESPONSIVENESS OF CLEAR CELL RENAL CELL CARCINOMA PATIENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-05-28 | — | — | US | claimed |
| US-20260144816-A1 | COMPOSITIONS AND METHODS FOR TREATING DEMENTIA | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2026-05-28 | — | — | US | claimed |
| US-20260144778-A1 | REGIMENS OF ESTROGEN RECEPTOR ANTAGONISTS | OLEMA PHARMACEUTICALS, INC. (US) | 2026-05-28 | — | — | US | claimed |
| EP-4223352-B1 | DRUG-COATED BALLOON CATHETERS FOR BODY LUMENS | UROTRONIC INC (US) | 2026-05-27 | — | — | EP | claimed |
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| EP-4306082-B1 | METHOD OF PRODUCING A HIGH PERFORMANCE BIOABSORBABLE STENT | JAPAN MEDICAL DEVICE TECH CO LTD (JP) | 2026-05-27 | — | — | EP | claimed |
| EP-4748448-A2 | USE OF MARIBAVIR FOR THE TREATMENT OF AND TREATMENT REGIMENS THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2026-05-27 | — | — | EP | claimed |
| CN-122075716-A | Medicine for treating tumor by combining recombinant oncolytic virus and small-molecule anticancer medicine | — | 2026-05-26 | — | — | CN | claimed |
| CN-116162546-B | Drug screening tumor organoid chip and drug screening method | DALIAN INSTITUTE OF CHEMICAL PHYSICS, CHINESE ACADEMY OF SCIENCES (CN) | 2026-05-26 | — | — | CN | claimed |
| CN-116209439-B | Cereblon protein modulators | Saint Jude Children's Research Hospital Ltd. (US) | 2026-05-26 | — | — | CN | claimed |
| US-20030144727-A1 | Medical device for delivering biologically active material | BOSTON SCIENTIFIC SCIMED, INC. | 2003-07-31 | — | — | US | claimed |
| US-20030139801-A1 | Delivery of therapeutic capable agents | AVANTEC VASCULAR CORPORATION (US) | 2003-07-24 | — | — | US | claimed |
| WO-2003039612-A1 | INTRALUMINAL DEVICE WITH A COATING CONTAINING A THERAPEUTIC AGENT | ATRIUM MEDICAL CORPORATION (US) | 2003-05-15 | — | — | WO | claimed |
| WO-2003039231-A2 | COMPOUNDS AND METHODS FOR TREATING TRANSPLANT REJECTION | ATHEROGENICS, INC. (US) | 2003-05-15 | — | — | WO | claimed |
| WO-2003037374-A1 | METHOD OF TREATMENT OF VULVAL VESTIBULITIS | METRIS THERAPEUTICS LIMITED (GB) | 2003-05-08 | — | — | WO | claimed |
| WO-2003034944-A1 | COATING OF STENTS FOR PREVENTING RESTENOSIS | HEMOTEQ GMBH (DE) | 2003-05-01 | — | — | WO | claimed |
| US-20030050692-A1 | Delivery of therapeutic capable agents | AVANTEC VASCULAR CORPORATION | 2003-03-13 | — | — | US | claimed |
| WO-2003009777-A2 | DELIVERY OF THERAPEUTIC CAPABLE AGENTS | AVANTEC VASCULAR CORPORATION (US) | 2003-02-06 | — | — | WO | claimed |
| WO-2003009779-A2 | DELIVERY OF THERAPEUTIC CAPABLE AGENTS | AVANTEC VASCULAR CORPORATION (US) | 2003-02-06 | — | — | WO | claimed |
| US-20020156022-A1 | Compounds and methods for treating transplant rejection | CRABTREE ACQUISITION CO, LLC | 2002-10-24 | — | — | US | claimed |